HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

L19-IL2 immunocytokine

derived from the single-chain antibody L19 and interleukin-2; has antineoplastic activity

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - L19-IL2 immunocytokine: 3

Experts

1.	Balza, Enrica: 2 articles (08/2019 - 11/2015)
2.	Carnemolla, Barbara: 2 articles (08/2019 - 11/2015)
3.	Conte, Romana: 2 articles (08/2019 - 11/2015)
4.	Mingari, Maria Cristina: 2 articles (08/2019 - 11/2015)
5.	Orecchia, Paola: 2 articles (08/2019 - 11/2015)
6.	Pietra, Gabriella: 2 articles (08/2019 - 11/2015)
7.	Bizzarri, Nicolò: 1 article (08/2019)
8.	Ferrero, Simone: 1 article (08/2019)
9.	Berndt, Alexander: 1 article (11/2010)
10.	Curigliano, Giuseppe: 1 article (11/2010)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 11/10/2015 - "Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts."
2.	Renal Cell Carcinoma (Grawitz Tumor) 11/01/2010 - "The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma."
3.	Carcinoma (Carcinomatosis) 08/23/2019 - "L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model."

Related Drugs and Biologics

1.	Syndecan-1 (Syndecan 1)